Subject: small molecule antagonists | lung cancer | bombesin receptor subtype-3 | RC648-665 | Original Research | Diseases of the endocrine glands. Clinical endocrinology | NMBR | GRPR | Endocrinology
While peptide antagonists for the gastrin-releasing peptide receptor (BB2R), neuromedin B receptor (BB1R), and bombesin (BB) receptor subtype-3 (BRS-3) exist, there is a need to develop non-peptide small molecule inhibitors for all three BBR. The BB agonist (BA)1 binds ... View more
1 Moreno P Ramos-Alvarez I Moody TW Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets (2016) 20:1055–73.10.1517/14728222.2016.1164694
3 Mantey SA Weber HC Sainz E Akeson M Ryan RR Pradhan TK Discovery of a high affinity radio ligand for the human orphan receptor, bombesin receptor subtype3, which demonstrates it has a unique pharmacology compared to other mammalin bombesin receptors. J Biol Chem (1997) 272:26062–71.10.1074/jbc.272.41.26062
8 Cuttitta F Carney DN Mulshine J Moody TW Fedorko J Fischler A Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (1985) 316:823–6.10.1038/316823a0
9 Giaccone G Battey J Gazdar AF Oie H Draoui M Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res (1993) 52:2732s–6s.